



Treatment for Bladder Cancer

Guest Editor:

Prof. Dr. Lukas Lusuardi

Department of Urology &
Andrology, Paracelsus Medical
University Salzburg, 5020
Salzburg, Austria

Deadline for manuscript
submissions:

closed (30 April 2021)

Message from the Guest Editor

Dear Colleagues,

After years of stable therapy approaches in non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC), uro-oncology dealing with this frequent tumour entity is finally facing several paradigmatic changes.

As it became clear that anti-PD-1 mAb therapy might be effective in BC without PD-L1 expression, PD-L1 expression in tumor tissue as a biomarker for anti-PD-1 mAb therapy should be reconsidered. Thus, the mechanism of how anti-PD-1 mAb therapy is effective against PD-L1 BC warrants further investigation.

Although it is known that the blood levels of soluble programmed cell death ligand 1 (sPD-L1) are elevated in various malignancies, the nature of sPD-L1 has not been thoroughly elucidated especially for BC. In this special issue of *CANCERS*, we are focusing this potential novel biomarker.

Additionally, antibody-drug conjugates represent a new therapeutic modality in urothelial cancer this other appealing new therapies are merging.

Prof. Dr. Lukas Lusuardi

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)